-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
SVB Leerink Comments on Eledon Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:ELDN)
SVB Leerink Comments on Eledon Pharmaceuticals, Inc.'s FY2027 Earnings (NASDAQ:ELDN)
Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Rating) – Research analysts at SVB Leerink issued their FY2027 earnings per share estimates for Eledon Pharmaceuticals in a report released on Tuesday, January 10th. SVB Leerink analyst T. Smith anticipates that the company will earn ($2.28) per share for the year. The consensus estimate for Eledon Pharmaceuticals' current full-year earnings is ($2.61) per share.
Get Eledon Pharmaceuticals alerts:Separately, HC Wainwright reiterated a "buy" rating on shares of Eledon Pharmaceuticals in a research report on Thursday, December 15th.
Eledon Pharmaceuticals Trading Down 2.1 %
Shares of Eledon Pharmaceuticals stock opened at $2.79 on Wednesday. The business's 50 day simple moving average is $2.49 and its 200-day simple moving average is $2.81. The stock has a market capitalization of $38.38 million, a price-to-earnings ratio of -1.05 and a beta of 1.81. Eledon Pharmaceuticals has a twelve month low of $2.03 and a twelve month high of $5.14.Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) last announced its quarterly earnings results on Monday, November 14th. The company reported ($0.73) earnings per share for the quarter, missing analysts' consensus estimates of ($0.68) by ($0.05).
Hedge Funds Weigh In On Eledon Pharmaceuticals
Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Dimensional Fund Advisors LP bought a new position in Eledon Pharmaceuticals in the 3rd quarter worth approximately $50,000. Renaissance Technologies LLC boosted its stake in Eledon Pharmaceuticals by 35.1% during the 1st quarter. Renaissance Technologies LLC now owns 18,473 shares of the company's stock valued at $73,000 after purchasing an additional 4,800 shares in the last quarter. State Street Corp boosted its stake in Eledon Pharmaceuticals by 10.5% during the 1st quarter. State Street Corp now owns 44,692 shares of the company's stock valued at $176,000 after purchasing an additional 4,257 shares in the last quarter. Ensign Peak Advisors Inc boosted its stake in Eledon Pharmaceuticals by 13.2% during the 3rd quarter. Ensign Peak Advisors Inc now owns 87,286 shares of the company's stock valued at $241,000 after purchasing an additional 10,186 shares in the last quarter. Finally, CM Management LLC boosted its stake in Eledon Pharmaceuticals by 8.9% during the 3rd quarter. CM Management LLC now owns 245,000 shares of the company's stock valued at $676,000 after purchasing an additional 20,000 shares in the last quarter. 45.59% of the stock is owned by institutional investors.
Eledon Pharmaceuticals Company Profile
(Get Rating)
Eledon Pharmaceuticals, Inc, clinical stage biopharmaceutical company, focuses on developing medicines for the patients living with autoimmune disease and amyotrophic lateral sclerosis (ALS), and requiring an organ or cell-based transplant. Its lead product candidate includes AT-1501, a humanized monoclonal antibody to target CD40 Ligand that is a molecule expressed on the surface of human immune system T cells, which is in Phase 2a clinical trials for the treatment of ALS, and Phase 2 clinical trials in islet cell transplantation for the treatment of type 1 diabetes.
Further Reading
- Get a free copy of the StockNews.com research report on Eledon Pharmaceuticals (ELDN)
- Bloom Energy Powers Up After an Upgrade, is it Worth the Risk?
- Why Hershey Is a Sweet Recession Stock
- Will Amazon Stock Be Delivering for Investors in 2023?
- The Analysts Shift Trucking Sentiment Back into Forward
- The Institutions Book A Flight With Boeing
Receive News & Ratings for Eledon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eledon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
Eledon制药公司(纳斯达克代码:ELDN-GET Rating)-SVB Leerink的研究分析师在1月10日(星期二)发布的一份报告中发布了他们对Eledon制药公司2027财年每股收益的预期。SVB Leerink分析师T·史密斯预计,该公司今年的每股收益为2.28美元。对Eledon PharmPharmticals目前全年收益的普遍预期为每股2.61美元。
到达伊莱顿制药公司警报:另外,在12月15日星期四的一份研究报告中,HC Wainwright重申了对Eledon PharmPharmticals股票的“买入”评级。
伊利登制药公司股价下跌2.1%
周三,Eledon PharmPharmticals的股票开盘报2.79美元。该业务的50日简单移动均线切入位在2.49美元,200日简单移动均线切入位在2.81美元。该股市值为3,838万美元,市盈率为-1.05,贝塔系数为1.81。Eledon PharmPharmticals的12个月低点为2.03美元,12个月高位为5.14美元。纳斯达克(ELDN-GET Rating)上一次公布季度收益是在11月14日(星期一)。该公司公布本季度每股收益为0.73美元,低于分析师普遍预期的0.68美元和0.05美元。
对冲基金买入伊利登制药
机构投资者和对冲基金最近增持或减持了该业务的股份。Dimension Fund Advisors LP在第三季度购买了Eledon PharmPharmticals的一个新头寸,价值约5万美元。复兴科技有限责任公司在第一季度将其在Eledon PharmPharmticals的持股增加了35.1%。复兴科技有限责任公司现在拥有18,473股该公司股票,价值73,000美元,在上个季度又购买了4,800股。道富集团在第一季度将其在Eledon PharmPharmticals的持股增加了10.5%。道富银行目前持有44,692股该公司股票,价值17.6万美元,此前该公司在上个季度又购买了4,257股。Ensign Peak Advisors Inc.在第三季度将其在Eledon PharmPharmticals的持股增加了13.2%。Ensign Peak Advisors Inc.在上个季度又购买了10,186股票后,现在拥有87,286股该公司股票,价值241,000美元。最后,CM Management LLC在第三季度将其在Eledon PharmPharmticals的持股增加了8.9%。CM Management LLC在上个季度又购买了20,000股后,现在拥有245,000股该公司股票,价值676,000美元。45.59%的股份由机构投资者持有。
伊利登制药公司简介
(获取评级)
Eledon PharmPharmticals,Inc.是一家临床阶段的生物制药公司,专注于为患有自身免疫性疾病和肌萎缩侧索硬化症(ALS)并需要器官或细胞移植的患者开发药物。它的主要候选产品包括AT-1501,一种人源化的针对CD40配体的单抗,是一种表达在人类免疫系统T细胞表面的分子,目前正处于治疗ALS的2a期临床试验,以及胰岛细胞移植治疗1型糖尿病的2期临床试验。
进一步阅读
- 免费获取StockNews.com关于Eledon制药的研究报告(ELDN)
- Bloom Energy在升级后启动,值得冒这个险吗?
- 好时为什么是一只甜蜜的衰退股票
- 亚马逊股票是否会在2023年为投资者提供服务?
- 分析师将货运情绪转回远期
- 各机构预订波音航班
接受《Eledon PharmPharmticals Daily》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Eledon PharmPharmticals和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧